Merck & Co., Inc.

Merck & Co., Inc. operates as a global leader in Pharmaceutical Preparations (SIC 2834), delivering innovative vaccines, oncology agents, and antiviral therapies that anchor its product portfolio for hospitals, clinics, and large health systems serving diverse patient populations; the company balances R&D-driven new chemical entities with established staples such as Keytruda and Gardasil, while also supplying contract manufacturing and biosafety services to biopharma partners. Operating under MRK, Merck navigates intense FDA scrutiny, patent cliffs, pricing reform pressures, and supply-chain risks that could affect drug availability, along with the ongoing challenges of clinical trial execution and reimbursement negotiations. The company’s patient safety protocols and compliance programs reflect the strict regulatory environment that defines its industry, and its reliance on global markets adds currency and geopolitical volatility into the risk mix. Investors reviewing the Form 10-Q filed Nov 1999 will find historical context for these themes, and anyone seeking updates can view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025